These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 21339258

  • 1. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
    Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, Sequist LV.
    Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
    [Abstract] [Full Text] [Related]

  • 2. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
    Lee EY, Khong PL, Lee VH, Qian W, Yu X, Wong MP.
    Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival.
    Lee Y, Lee HJ, Kim YT, Kang CH, Goo JM, Park CM, Paeng JC, Chung DH, Jeon YK.
    Korean J Radiol; 2013 Mar; 14(2):375-83. PubMed ID: 23483676
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
    Guan J, Xiao NJ, Chen M, Zhou WL, Zhang YW, Wang S, Dai YM, Li L, Zhang Y, Li QY, Li XZ, Yang M, Wu HB, Chen LH, Liu LY.
    Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, Chen T, Yang J, Jing M, Chen F, Wang C, Sun H, Huang Y.
    Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
    Liu A, Han A, Zhu H, Ma L, Huang Y, Li M, Jin F, Yang Q, Yu J.
    Oncotarget; 2017 May 16; 8(20):33736-33744. PubMed ID: 28422710
    [Abstract] [Full Text] [Related]

  • 16. Correlation between EGFR mutation status and F18 -fluorodeoxyglucose positron emission tomography-computed tomography image features in lung adenocarcinoma.
    Zhu L, Yin G, Chen W, Li X, Yu X, Zhu X, Jiang W, Jia C, Chen P, Zhang Y, Lu D, Yu L, Li X, Xu W.
    Thorac Cancer; 2019 Apr 16; 10(4):659-664. PubMed ID: 30776196
    [Abstract] [Full Text] [Related]

  • 17. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.
    Na II, Byun BH, Kim KM, Cheon GJ, Choe du H, Koh JS, Lee DY, Ryoo BY, Baek H, Lim SM, Yang SH, Kim CH, Lee JC.
    Lung Cancer; 2010 Jan 16; 67(1):76-80. PubMed ID: 19371962
    [Abstract] [Full Text] [Related]

  • 18. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers SA, van Tinteren H, Klomp HM.
    Ann Surg Oncol; 2014 Sep 16; 21(9):2831-7. PubMed ID: 24845729
    [Abstract] [Full Text] [Related]

  • 19. Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer.
    Shi A, Wang J, Wang Y, Guo G, Fan C, Liu J.
    Ann Nucl Med; 2022 Apr 16; 36(4):393-400. PubMed ID: 35084711
    [Abstract] [Full Text] [Related]

  • 20. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):e551-5. PubMed ID: 22417800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.